

Guidelines Support the Use of EndoPredict

International & National Clinical Practice Guidelines

support the use of gene expression assays to identify women with ER+, HER2- early stage breast cancer with low risk disease who may safely forgo chemotherapy.

EndoPredict

is included in many International and National Clinical Practice Guidelines:

INTERNATIONAL GUIDELINES

ASCO

American Society of Clinical Oncology

- ...may be used to guide decisions on adjuvant systemic chemotherapy in ER+, HER2- node negative breast cancer patients.¹

AJCC

American Joint Committee on Cancer

- ...low risk score, in HR+, HER2-, N0 patients, regardless of T size, places the tumor into the same prognostic category as T1a-T1b N0 M0 with a level of evidence II.²

NCCN

National Comprehensive Cancer Network

- Node Negative: ...may be considered to help assess risk of recurrence...
- Node Positive: Consider to assess prognosis and determine chemotherapy benefit.³



EndoPredict[®]
Breast Cancer Recurrence Test

EGMT

European Group on Tumor Markers

- ...may be used for predicting outcome and aiding adjuvant therapy decision-making in hormone receptor-positive, HER2-negative patients that are either lymph node negative or lymph node positive (with up to 3 positive lymph nodes).⁴

St. Gallen

International Expert Consensus

- The Panel strongly endorsed the value of genomic assays for determining whether to recommend chemotherapy in T1/T2 N0 tumors, T3 N0 tumors, and TxN1 (1 to 3 positive LN).
- Women with higher risk cancers - those with involved lymph nodes at diagnosis and higher risk genomic signature scores - are at greater risk for late recurrence and thus derive more absolute numerical benefit from extended therapy.⁵


ESMO

European Society of Medical Oncology

- ...may be used to gain additional prognostic and/or predictive information to complement pathologic evaluation and to predict chemotherapy benefit for N0 and N+ (1-3 positive lymph nodes) disease in uncertain cases.⁶

NATIONAL GUIDELINES

EndoPredict is included in:



1. Harris et al. J Clin Oncol 2016
2. Amin et al. (Eds.) AJCC Cancer Staging Manual- Eight Edition Printed Book ISBN 978-3-319-40617-6 Springer International Publishing
3. NCCN: www.nccn.org
4. Duffy et al. Eur J Cancer 2017
5. Burstein et al. Ann. Oncol. 2019
6. Cardoso et al. Ann. Oncol. 2019
7. Linee Guida AIOM Neoplasie della Mammella; <http://www.aiom.it/professionisti/documenti-scientifici/linee-guida/1,413,1>
8. AGO Breast Committee. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2019.1. www.ago-online.de, s. 151
9. Leitlinienprogramm Onkologie | S3-Leitlinie Mammakarzinom | Version 4.1 | September 2018
10. Clinical Utility of Multigene Profiling Assays in Invasive Early-Stage Breast Cancer Recommendation Report MOAC 4: June 2016 https://www.cancercare.on.ca/toolbox/qualityguidelines/clin-program/pathlabs/pebc_molecon/
11. www.more-conference.com/media/pdf/PredictiveBiomarkers_MOPE2017_v1.pdf
12. NICE: <https://www.nice.org.uk/guidance/dg34>
13. HAS: www.has-sante.fr/portail/jcms/c_2748998/fr/utiliteclinique-des-signatures-genomiques-dans-le-cancer-du-sein-de-stade-precoce-rapport-d-evaluation?xtmc=&xtrc=1
14. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Colima 2017 <http://www.consensocancermamario.com/>
15. Garcia-Saenz et al. Clin Transl Oncol 2015
16. Filipits et al.: Clin Cancer Res. 2011
17. Sestak et al. Breast Cancer Res Treat. 2019
18. Filipits et al. Clin Cancer Res. 2019



The ONLY test that answers the following three important clinical questions...

- Can chemotherapy be avoided?¹⁶
- What is the absolute benefit from chemotherapy?¹⁷
- Can endocrine therapy be stopped after 5 years?¹⁸

... to optimize treatment for your breast cancer patients

* Filipits et al., Clin Cancer Res 2011; Martin M. et al., Breast Cancer Res 2014; Buus et al., J Natl Cancer Inst 2016



Myriad Genetics GmbH
Leutschenbachstrasse 95
8050 Zurich - Switzerland
www.myriadgenetics.eu
www.endopredict.com

